Mirati Therapeutics, Inc. (NASDAQ:MRTX – Get Rating) EVP Jamie Christensen sold 624 shares of Mirati Therapeutics stock in a transaction on Monday, May 23rd. The stock was sold at an average price of $63.54, for a total value of $39,648.96. Following the sale, the executive vice president now owns 86,804 shares of the company’s stock, valued at $5,515,526.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
MRTX traded down $1.24 on Tuesday, hitting $52.51. The company had a trading volume of 1,319,520 shares, compared to its average volume of 1,047,892. The stock has a fifty day moving average price of $63.00 and a 200-day moving average price of $95.11. Mirati Therapeutics, Inc. has a 12-month low of $32.96 and a 12-month high of $195.99. The stock has a market capitalization of $2.92 billion, a price-to-earnings ratio of -4.39 and a beta of 1.64.
Mirati Therapeutics (NASDAQ:MRTX – Get Rating) last posted its earnings results on Wednesday, May 4th. The biotechnology company reported ($3.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.37) by ($0.03). The business had revenue of $0.71 million during the quarter, compared to the consensus estimate of $0.18 million. During the same quarter in the previous year, the business earned ($2.67) EPS. Mirati Therapeutics’s revenue was up 6990.0% compared to the same quarter last year. On average, research analysts forecast that Mirati Therapeutics, Inc. will post -14.37 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Sector Gamma AS grew its stake in Mirati Therapeutics by 0.4% in the fourth quarter. Sector Gamma AS now owns 26,106 shares of the biotechnology company’s stock valued at $3,829,000 after purchasing an additional 106 shares during the last quarter. Gotham Asset Management LLC grew its stake in shares of Mirati Therapeutics by 8.7% during the fourth quarter. Gotham Asset Management LLC now owns 1,581 shares of the biotechnology company’s stock worth $232,000 after acquiring an additional 126 shares during the last quarter. Xponance Inc. grew its stake in shares of Mirati Therapeutics by 4.0% during the fourth quarter. Xponance Inc. now owns 3,912 shares of the biotechnology company’s stock worth $574,000 after acquiring an additional 150 shares during the last quarter. Signaturefd LLC grew its stake in shares of Mirati Therapeutics by 102.4% during the first quarter. Signaturefd LLC now owns 338 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 171 shares during the last quarter. Finally, Advisor Group Holdings Inc. grew its stake in shares of Mirati Therapeutics by 57.4% during the third quarter. Advisor Group Holdings Inc. now owns 488 shares of the biotechnology company’s stock worth $87,000 after acquiring an additional 178 shares during the last quarter.
Several analysts have recently weighed in on the company. Citigroup decreased their target price on Mirati Therapeutics from $227.00 to $208.00 in a research report on Thursday, May 5th. JMP Securities upgraded Mirati Therapeutics from a “market perform” rating to an “outperform” rating and set a $72.00 target price for the company in a research report on Tuesday, June 7th. BMO Capital Markets reiterated a “buy” rating and set a $80.00 target price on shares of Mirati Therapeutics in a research report on Tuesday, June 7th. Oppenheimer decreased their target price on Mirati Therapeutics to $85.00 in a research report on Thursday, June 9th. Finally, Jonestrading restated a “buy” rating and set a $100.00 price target on shares of Mirati Therapeutics in a research note on Saturday, June 4th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $142.43.
Mirati Therapeutics Company Profile (Get Rating)
Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development.